SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38950981.
- Also identified by DOI 10.3949/ccjm.91a.23093.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite current therapies, heart failure and chronic kidney disease continue to be major causes of morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have recently become standard-of-care therapy for these conditions. This review summarizes important randomized controlled trials of SGLT-2 inhibitors and guidelines for using these agents in patients with heart failure and chronic kidney disease in both clinic and hospital settings.
Medical subject headings
- Sodium-Glucose Transporter 2 Inhibitors
- Heart Failure
- Renal Insufficiency, Chronic